Violich Capital Management Inc. Has $3.97 Million Stake in CVS Health Corporation $CVS

Violich Capital Management Inc. trimmed its holdings in CVS Health Corporation (NYSE:CVS) by 11.1% in the fourth quarter, Holdings Channel reports. The fund owned 49,997 shares of the pharmacy operator’s stock after selling 6,267 shares during the period. Violich Capital Management Inc.’s holdings in CVS Health were worth $3,968,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Corundum Trust Company INC acquired a new position in shares of CVS Health during the third quarter worth about $29,000. Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the fourth quarter worth about $29,000. GoalVest Advisory LLC acquired a new position in shares of CVS Health during the fourth quarter worth about $32,000. Finally, Financial Consulate Inc. boosted its position in shares of CVS Health by 99.6% during the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock worth $40,000 after buying an additional 249 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS topped Q1 earnings and revenue expectations and raised full‑year 2026 guidance (adjusted EPS guidance to $7.30–7.50), driven by better insurance results and reserve benefits — the core catalyst for today’s rally. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Major sell‑side firms raised price targets and reiterated Buy calls (notably UBS to $100), amplifying upside expectations and investor demand. These upgrades flow directly from the stronger-than-expected insurance margins and clearer guidance. CVS Health (NYSE:CVS) Price Target Raised to $100.00 at UBS Group
• Positive Sentiment: Operational momentum: increased prescription volume and a healthier Aetna (Q1 profit ~ $2.9B; medical benefit ratio improvement) underpin recurring cash flow and margin recovery expectations. CVS’s increased prescription volume leads to solid Q1
• Neutral Sentiment: Strategic initiatives — expanded biosimilar formularies, AI and community programs — position CVS to lower drug costs and improve care coordination, but benefits will play out over multiple quarters. CVS Health Bets On Biosimilars And AI To Support Affordable Care
• Neutral Sentiment: Valuation debate: after a strong one‑year run, some pieces assess whether current prices already reflect recovery, making further upside dependent on sustained insurance margin improvement and PBM performance. Is CVS Health (CVS) Still Attractive After Its Strong 1 Year Share Price Run?
• Negative Sentiment: Structural risks remain: critics flag longer‑term margin pressure in the PBM business and warn the near‑term insurance tailwind may be temporary — these concerns could cap multiple expansion if not addressed. How CVS Health’s Transformation Is Facing A Hard Valuation Floor

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CVS shares. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. DA Davidson increased their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday. Barclays increased their price target on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Thursday. HSBC increased their price target on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Wells Fargo & Company restated an “overweight” rating on shares of CVS Health in a research note on Friday. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $95.88.

CVS Health Price Performance

Shares of NYSE CVS opened at $87.34 on Friday. The business’s 50 day moving average is $76.86 and its 200-day moving average is $78.03. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $88.63. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.78. The firm has a market cap of $111.93 billion, a P/E ratio of 38.47, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the company earned $2.25 EPS. The company’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts predict that CVS Health Corporation will post 7.14 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.